FIGURE 9.

Summary diagram of our results. PSMA‐specific CAR‐modified NK92 cells were activated through the specific recognition of PSMA on PCa cells, and CAR NK‐92 cell expression of PD‐L1 was upregulated via the PI3K/AKT/mTOR signalling pathway, while C4‐2 cell expression of PD‐L1 was upregulated via the IFN‐γ‐mediated JAK1/2‐STAT1 pathway. On the one hand, atezolizumab potentiated CAR NK‐92 cell cytotoxicity by directly acting on PD‐L1 expressed on CAR NK‐92 cells; on the other hand, atezolizumab unleashed CD8⁺ T cells by blocking the canonical PD‐L1/PD‐1 axis; MICA/B, MHC class I chain‐related protein A and B; NKG2D, NK group 2 member D; PSMA, prostate‐specific membrane antigen